attyloid’s sFIDA Used in Detecting Parkinson’s-Related Biomarkers in Stool Samples
A recent study published in Nature Parkinson’s Diease has used attyloid’s sFIDA technology to measure α-synuclein aggregates in stool, a potential biomarker for Parkinson’s disease. The study found elevated levels of these aggregates in patients with isolated rapid eye movement sleep behavior disorder (iRBD), compared to healthy controls and Parkinson’s patients. The findings suggest that sFIDA could offer a less invasive method for early detection of conditions related to Parkinson’s.